PYC Therapeutics Limited (ASX:PYC)

Australia flag Australia · Delayed Price · Currency is AUD
1.280
-0.010 (-0.78%)
Aug 29, 2025, 4:10 PM AEST
-0.78%
Market Cap746.57M
Revenue (ttm)23.49M
Net Income (ttm)-50.30M
Shares Out583.26M
EPS (ttm)-0.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume79,230
Average Volume502,848
Open1.280
Previous Close1.290
Day's Range1.245 - 1.280
52-Week Range0.950 - 2.080
Beta0.56
RSI47.56
Earnings DateAug 29, 2025

About PYC Therapeutics

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeuti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 5
Stock Exchange Australian Securities Exchange
Ticker Symbol PYC
Full Company Profile

Financial Performance

In 2025, PYC Therapeutics's revenue was 23.49 million, an increase of 6.51% compared to the previous year's 22.06 million. Losses were -50.30 million, 33.3% more than in 2024.

Financial Statements

News

There is no news available yet.